Market access decisions are evidence decisions. A payer is deciding whether to fund a therapy for a defined population, under defined rules, at a defined net cost, with defined uncertainty. Your job is to make that decision easy to justify and easy to implement. That requires more than “good data.” It requires a sequenced proof story that links clinical benefit to the payer’s comparator, translates benefit into affordability and predictability, and anticipates how criteria will be applied in real care settings.
7.1 Designing the Integrated Evidence Generation Plan (IEGP)
The Integrated Evidence Generation Plan (IEGP) connects access ambition to specific studies, analyses, and communication artifacts. It is integrated because it coordinates randomized trials, real-world studies, economic modeling, and humanistic evidence around the same payer claims, timed to decision points in priority markets. A strong IEGP prevents a common failure mode: the organization reaches late Phase 3 with regulatory-ready evidence but without credible answers to payer objections on comparators, durability, and affordability.
Start by expressing ambition in payer terms. Access ambition: the intended funded population, expected restrictions, and minimum acceptable coverage conditions by market cluster. Avoid slogans such as “broad access.” Write criteria: line of therapy, diagnostic confirmation, severity markers, prior treatments, site-of-care expectations, and renewal logic. This forces early trade-offs and anchors the evidence plan to a realistic reimbursement outcome.
Define the few claims that will anchor the value story. Claim: a payer-relevant statement about benefit, appropriate use, or system impact that will appear consistently in submissions and negotiations. Examples include fewer severe events in a high-risk subgroup, meaningful symptom and function improvement, reduced rescue medication use, improved tolerability that supports persistence, or a durability profile that supports long-term value. Limit claims to what you can defend transparently, and separate what is observed from what is modeled.
Then map uncertainty in a decision-ready way. Uncertainty: a specific question that could change the payer’s value assessment, budget impact view, or acceptable conditions of use. Common uncertainties include comparator mismatch, generalizability to routine practice, durability beyond follow-up, heterogeneity across subgroups, safety in broader use, and the risk that utilization expands beyond the high-value segment. For each uncertainty, define the evidence path that reduces it and the timing relative to the payer decision (before submission, during review, or post-launch under a defined commitment).
Translate claims and uncertainties into workstreams with owners and timing. Separate what must be proven pre-launch from what can be credibly committed post-launch. Avoid “nice-to-have” studies that do not change a payer decision. When evidence is missing, make a deliberate choice: narrow the claim, narrow the population, or invest in the evidence. That is what keeps the program coherent and keeps negotiations grounded in defensible trade-offs.
Finally, treat the IEGP as a managed asset. Update it at Phase 2 end, pivotal lock, pre-submission, launch, and year-one review. Each update should record what changed, why, and which payer decision it affects most directly.
Use this IEGP design checklist as your minimum viable plan.
- Decision points: key submission windows, formulary cycles, tender dates, and reassessment triggers in priority markets.
- Comparator plan: funded comparator by market cluster and how differences from trial comparators will be handled.
- Population boundaries: expected reimbursed criteria and the restriction boundaries most likely to be imposed.
- Endpoints: payer-relevant endpoints, including what is patient-relevant versus what requires linking evidence.
- Top uncertainties: the five to eight questions most likely to drive restrictions, delay, or net pressure.
- Evidence workstreams: RCT, RWE, economic, and PRO studies mapped to each uncertainty with owners and timelines.
- Feasibility: data capture reality in routine practice, including which outcomes can be measured and validated.
- Artifacts: when the GVD, AMCP dossier, country modules, and negotiation materials will be built and refreshed.
- Governance: decision rights for changing claims, endpoints, and models once pivotal trials are committed.
Operate the IEGP as a living plan. Refresh it at predictable milestones: end of Phase 2, pivotal finalization, pre-submission, launch, and post-launch year 1. Each refresh should record what changed and why. This documentation is not bureaucracy; it protects coherence when multiple functions work in parallel and reduces the spread of “shadow versions” of the value story across countries.
7.2 Clinical Evidence: RCTs, RWE, and Post-Marketing Commitments
Clinical evidence anchors access, but payers apply a different test than regulators. Regulators ask whether benefit-risk supports approval. Payers ask whether incremental benefit justifies funding relative to therapies they already pay for, in the population they will reimburse, in routine practice, and under affordability constraints. That difference creates recurring challenges: comparator alignment, endpoint relevance, and durability.
RCTs: Randomized controlled trials remain the highest-trust evidence for causal inference. For access, the highest-leverage design choices are those that determine payer comparability: comparator, population, and endpoints. If the comparator does not match standard of care in key markets, you will rely on indirect comparisons and face skepticism. If the trial population excludes patients with common comorbidities or the elderly, payers will assume uncertainty and convert it into tighter criteria, renewal hurdles, or slower uptake. Endpoint choice matters as much as statistical significance. Payers and HTA bodies reward patient-relevant outcomes and penalize endpoints that are hard to interpret in the real pathway unless you can build a linking argument that technical assessors will accept.
Build payer awareness into trial strategy wherever feasible. If head-to-head trials are not possible, plan indirect comparisons early, including the evidence needed to justify assumptions and assess bias. If restrictions by line of therapy, biomarker, or severity are likely, ensure the program supports that segmentation with credible subgroup evidence and pre-specified hypotheses. Plan durability intentionally. If follow-up will be short at launch, define how extrapolation will be supported, what evidence will be used to justify it, and what post-launch evidence will be delivered to reduce uncertainty before reassessment becomes punitive.
RWE: Real-world evidence is best used to reduce uncertainties that RCTs cannot resolve: baseline burden and comparator outcomes in routine practice, sequencing and switching patterns, adherence and persistence, heterogeneity of benefit, and real-world resource use. Use RWE in two waves. Pre-launch RWE: establishes baseline patterns and outcomes under current care, strengthening the unmet need narrative and improving budget impact realism. Post-launch RWE: evaluates performance under reimbursed criteria, supports reassessment, and helps defend access against new comparators and policy shifts.
Design RWE with the payer decision in mind. Start with a precise question, then choose the simplest design that can credibly answer it. Be explicit about confounding and selection bias. If a payer expects causal inference, do not present a descriptive study as if it were causal. Conversely, do not over-engineer methods if the payer’s primary need is baseline utilization and resource use for budget impact. The most common RWE failure is answering an interesting scientific question that does not change a payer decision or improve implementability.
Post-marketing commitments: Commitments are how many systems convert uncertainty into conditional access rather than a “no.” Commitments work when they are specific, executable, and tied to the uncertainty that mattered to the decision maker. They fail when they are vague, burdensome, or disconnected from reassessment criteria. When proposing commitments, define five components: Purpose: which uncertainty is addressed; Endpoint: what will be measured and why it is decision-relevant; Population: who is included, aligned to reimbursed criteria; Data source: how data will be captured and validated; Decision trigger: what will happen when results meet or miss thresholds.
Use this clinical evidence quality check before finalizing payer-facing narratives.
- Comparator match: evidence speaks to the funded comparator or a defensible indirect comparison plan exists.
- Population match: evidence aligns with expected reimbursed criteria and restricted subgroups are characterized.
- Endpoint relevance: endpoints are patient-relevant or supported by a credible linking chain.
- Durability story: long-term assumptions are explicit and supported by follow-up or commitments.
- Transparency: limitations and uncertainty are stated clearly, with a plan to manage them.
The strongest clinical story for access is not “the trial met endpoints.” It is “we know where benefit is strongest, we can define appropriate use, and we can reduce remaining uncertainty without creating operational burden.”
7.3 Economic and Humanistic Evidence: Cost-Effectiveness, Budget Impact, PROs
Economic and humanistic evidence translates clinical benefit into the payer’s resource-allocation language. It answers two practical questions: can the system afford this under realistic utilization, and will patients experience meaningful improvements that are likely to be realized in routine practice. The quality standard is decision relevance, transparency, and coherence with the clinical narrative.
Cost-effectiveness: Cost-effectiveness models estimate incremental cost per unit of health benefit under a defined comparator and time horizon. Their practical value is to reveal drivers, test robustness, and clarify trade-offs, not to produce a single “right” number. Reviewers will probe comparator choice, time horizon, discontinuation assumptions, utility values, resource use, and extrapolation of long-term effects. Build models so a skeptical assessor can trace key inputs, understand the structure, and see how results move under plausible ranges. If your result hinges on one fragile assumption, say so and plan how to reduce that fragility.
Budget impact: Budget impact is frequently the binding constraint. A payer can accept value and still restrict access because near-term spend is too high or too uncertain. Strong budget impact analyses are realistic, segmented, and aligned to the payer’s budget silo. Start with epidemiology and eligibility, then apply criteria, uptake curves, duration, discontinuation, and switching. Present base, conservative, and high-uptake scenarios and show what drives variance. Avoid double counting offsets, and be explicit about whether offsets are likely to occur in the payer’s accounting silo or in a different part of the system.
PROs and humanistic outcomes: Patient-reported outcomes capture symptom relief, function, and quality of life in ways that matter to patients and can matter to payers, especially when mortality endpoints are infeasible, comparator differences are modest, or adherence drives real-world effectiveness. Use validated instruments, define clinically meaningful change thresholds, and address missing data transparently. Humanistic evidence can also strengthen appropriate-use logic by clarifying which patients have the greatest burden and the most room for improvement, which can support targeting arguments that protect affordability.
Economic and humanistic evidence should reflect implementation reality. Site of care, monitoring burden, diagnostic requirements, and adherence patterns can materially change cost and outcomes. If your model assumes perfect persistence but the pathway implies high abandonment, payers will discount the analysis. Align the economic story to the operational pathway you expect to exist and explain what will be done to make that pathway workable.
Use this checklist to keep the economic package decision-ready.
- Decision alignment: models answer the payer’s question in that market and budget context.
- Comparator coherence: comparator matches the clinical story and local standard of care.
- Population coherence: modeled population matches expected reimbursed criteria and restriction boundaries.
- Key drivers: top drivers are identified and explained in plain language.
- Sensitivity: results are tested under realistic ranges and show where conclusions are stable versus fragile.
- PRO credibility: instruments are validated and meaningful change thresholds are defined and supported.
When uncertainty remains, do not try to model it away. Use modeling to identify risk, then manage risk with feasible levers: targeting, phased coverage, measurable safeguards, or contract structures that reduce budget volatility.
7.4 Value Dossiers and Payer Communication Materials
Payers do not experience evidence as a collection of studies; they experience it as a dossier and a decision conversation. Dossiers translate evidence into a coherent, auditable case for funding and appropriate use. The most common dossier failure is inconsistency: different population definitions across sections, different comparators across analyses, or economic assumptions that do not match the clinical narrative. Inconsistency is interpreted as bias and often results in restrictions.
Global Value Dossier: The GVD is the master asset that defines core claims, summarizes evidence with transparent grading, and provides the base modeling approach. Its purpose is a stable single source of truth that local teams can adapt to local comparators, costs, and policy context without rewriting the scientific spine. The GVD should define what is non-negotiable versus what is designed to be localized, including approved ranges for key assumptions.
AMCP dossier: In the United States, many payers expect a dossier aligned to AMCP conventions. The emphasis is practical: clinical evidence review, economic approach, budget impact, and information that supports formulary and medical policy decisions. Strong AMCP-style materials anticipate implementation, including how criteria can be operationalized and which steps in the prescribing-to-payment pathway may create denials or delays.
Most programs also require a small set of companion materials tailored to specific stakeholders. Examples include an executive payer deck for decision makers, a technical appendix that enables model review, a criteria rationale that explains appropriate-use logic, and implementation guidance that clarifies documentation and monitoring expectations where permitted. Keep every artifact aligned to the same claims and the same population and comparator definitions. If stakeholders hear different versions of “who qualifies” or “what we are comparing against,” you create rework internally and skepticism externally.
Build dossiers modularly so they can be localized and updated without creating version chaos. Use this structure as a default.
- Executive summary: the case for funding, written for decision makers.
- Disease and pathway: unmet need, current pathway, and comparator rationale.
- Clinical evidence: efficacy, safety, comparative analyses, and subgroup story aligned to likely criteria.
- Economic evidence: cost-effectiveness approach and results, plus budget impact scenarios and drivers.
- Humanistic evidence: PRO and functioning outcomes, when decision-relevant.
- Appropriate use: selection, sequencing, monitoring, and implementation considerations.
- Evidence gaps: what remains uncertain and how it will be managed post-launch.
- Technical appendices: methods, assumptions, sensitivity analyses, and data sources.
Before finalization, run a structured cross-check. Consistency check: an internal review that confirms the same population, comparator, endpoints, and time horizon appear across clinical summaries, economic models, budget impact, and the executive narrative. Treat this as required. It is one of the fastest ways to reduce restrictions driven by perceived inconsistency.
7.5 Managing Evidence Gaps and Uncertainty at Launch
Uncertainty at launch is inevitable. The question is whether uncertainty becomes a manageable set of conditions or an uncontrolled set of restrictions. Managing uncertainty is a core access skill because payers use uncertainty to narrow criteria, delay decisions, or demand concessions. You improve outcomes by naming gaps early, choosing containment levers that match the uncertainty, and making commitments that are feasible.
Evidence gap: a specific unanswered question at launch that could change assessment of value, budget impact, or appropriate use. Common gaps include durability beyond trial follow-up, comparative effectiveness versus an untested local comparator, real-world adherence, and broader safety experience. If you do not define gaps, reviewers will define them conservatively and often with broader restrictions than you intended.
For each gap, choose a containment strategy that matches the gap type and market mechanics. Most strategies fall into five levers.
- Targeting: fund the subgroup with clearest benefit, then expand as evidence accrues.
- Conditional access: accept reassessment tied to evidence milestones.
- Evidence commitments: run specific studies or registries that answer the payer’s uncertainty.
- Risk-sharing: align financial terms to uncertainty about durability or utilization.
- Implementation controls: define appropriate use and monitoring to reduce misuse without excessive friction.
Operational realism is the filter. Outcomes-linked approaches require measurable endpoints and reliable data capture. Evidence commitments require governance and acceptable site burden. Targeting requires criteria clinicians can apply and payers can administer. If feasibility is weak, the “solution” becomes a new barrier and can backfire.
Create a launch uncertainty register that is short but specific, and review it alongside pricing and contracting guardrails. Use this template.
- Uncertainty: the exact question that remains unresolved.
- Impact: expected payer response if unresolved.
- Current evidence: what is defensible now and the limits of that defense.
- Mitigation: which lever will be used and what give-get is expected.
- Feasibility: data source, owner, timeline, and burden assessment.
- Trigger: what new data or event will cause a strategy update or reassessment request.
Four failure modes recur. Overpromising: offering tracking that cannot be executed; fix by choosing endpoints and data sources that already exist in the system. Overgeneralizing: claiming broad benefit when evidence is strongest in a subset; fix by aligning launch criteria to evidence strength and planning expansion. Underestimating comparator shifts: ignoring competitor entry or guideline changes that will reframe value; fix by scenario planning and by pre-defining what new evidence, messaging, or contracting posture will be needed if the comparator changes. Confusing evidence with implementation: assuming that a favorable assessment guarantees paid utilization; fix by connecting evidence to workable criteria and monitoring the early signals of friction.
Post-launch evidence is part of your access contract with the system. If you commit to evidence generation, deliver it on time, in a credible form, and in a way that clearly reduces the uncertainty that mattered to the decision maker. That reliability builds trust, improves the odds that restrictions loosen rather than tighten, and makes access more durable as reassessments and competitive pressures arise.
Evidence and value demonstration is not a separate technical exercise. It is the discipline that determines whether access is broad or narrow, fast or slow, and durable or fragile. Build an integrated plan, translate benefit into payer-relevant economics and humanistic outcomes, communicate with coherent dossiers, and manage uncertainty with feasible levers. That is how you make access real at the point of care.
